Status:
COMPLETED
Comparison of Ease of Use and Acceptability of Intranasal and Injectable Glucagon Among Providers Administering it to Children or Adolescents With Type 1 Diabetes (BETTER-ING)
Lead Sponsor:
CHU de Quebec-Universite Laval
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Juvenile Diabetes Research Foundation
Conditions:
Diabetes Mellitus, Type 1
Hypoglycemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background : The benefits of good glycemic control are clearly established. However, achieving glycemic targets comes at the expense of the risk of hypoglycemia. Repeated episodes of severe hypoglycem...
Eligibility Criteria
Inclusion
- Parent or primary caregiver of a child or adolescent (\<18 years old) diagnosed with type 1 diabetes OR
- Any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, animators, teacher candidates, etc.) AND
- Legal age
- Able to participate
Exclusion
- Working in the health field and teach glucagon injection or use it regularly in their duties
- Not understanding French (for viewing the videos)
Key Trial Info
Start Date :
March 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05395000
Start Date
March 19 2021
End Date
September 22 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de recherche du CHU de Québec - Université Laval
Québec, Canada, G1V 4G2